中药三阴方治疗三阴性乳腺癌的回顾性队列研究

辛颖; 刘胜; 秦悦农; 孙霃平

doi:10.16305/j.1007-1334.2021.2007017

您当前的位置：

首页 >

文章列表页 >

中药三阴方治疗三阴性乳腺癌的回顾性队列研究

临床试验 | 更新时间：2022-08-03

- 中药三阴方治疗三阴性乳腺癌的回顾性队列研究
- A retrospective cohort study on treatment of triple-negative breast cancer with Sanyin Decoction
- 上海中医药杂志 2021年55卷第5期页码：63-66
- 作者机构：
  
  1.上海中医药大学附属龙华医院中西医结合乳腺科（上海　200030）
- 作者简介：
  
  辛颖，女,博士研究生，主要从事中医药防治乳腺疾病的相关研究工作
  刘胜，教授，博士研究生导师；E-mail：lshtcm@163.com
- 基金信息：
  
  国家中医药管理局中医药行业科研专项(201507001-10)
- DOI：10.16305/j.1007-1334.2021.2007017
  中图分类号：
扫描看全文
辛颖, 刘胜, 秦悦农, 等. 中药三阴方治疗三阴性乳腺癌的回顾性队列研究[J]. 上海中医药杂志, 2021,55(5):63-66.

Ying XIN, Sheng LIU, Yuenong QIN, et al. A retrospective cohort study on treatment of triple-negative breast cancer with Sanyin Decoction[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(5):63-66.
辛颖, 刘胜, 秦悦农, 等. 中药三阴方治疗三阴性乳腺癌的回顾性队列研究[J]. 上海中医药杂志, 2021,55(5):63-66. DOI： 10.16305/j.1007-1334.2021.2007017.

Ying XIN, Sheng LIU, Yuenong QIN, et al. A retrospective cohort study on treatment of triple-negative breast cancer with Sanyin Decoction[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(5):63-66. DOI： 10.16305/j.1007-1334.2021.2007017.

摘要

目的,2,探讨中药三阴方对三阴性乳腺癌患者术后无病生存期的影响。,方法,2,采用回顾性队列研究的方法，纳入三阴性乳腺癌中药暴露组（三阴方参与治疗）患者156例，非暴露组（无三阴方参与治疗）患者192例。比较两组术后6个月、12个月、18个月、24个月的无病生存率，绘制Kaplan-Meier生存曲线，建立Cox回归模型分析影响三阴性乳腺癌术后复发转移的因素。,结果,2,①术后6个月、12个月两组无病生存率差异无统计学意义（,P,>,0.05）；术后18个月中药暴露组、非暴露组的无病生存率分别为98.08%、92.19%，组间差异有统计学意义（,P,<,0.05）；术后24个月中药暴露组、非暴露组的无病生存率分别为98.08%、89.06%，组间差异有统计学意义（,P,<,0.05）。②Cox回归分析结果显示，转移淋巴结分期（,P,<,0.001）、是否有中药干预（,P,<,0.001）是影响三阴性乳腺癌患者术后复发转移的因素，其中中药干预是保护因素[,HR,=0.191（95% ,CI,：0.083～0.443）]，转移淋巴结分期是危险因素，且分级越高复发转移风险越高；发病年龄、病理分级、肿块大小、Ki-67阳性百分比、病理类型及有无接受新辅助化疗与预后无关（,P,>,0.05）。,结论,2,中药三阴方对三阴性乳腺癌有辅助治疗效果，有利于提高患者的无病生存期；转移淋巴结分期是三阴性乳腺癌术后复发转移的危险因素，服用中药三阴方是保护因素。

Abstract

Objective,2,To explore the effect of traditional Chinese medicine (TCM) Sanyin Decoction on postoperative disease-free survival (DFS) of patients with triple-negative breast cancer (TNBC).,Methods,2,A retrospective cohort study was conducted by enrolling 156 TNBC patients in the TCM-exposed group (treatment with Sanyin Decoction involved) and 192 TNBC patients in the non-TCM-exposed group (treatment without Sanyin Decoction involved). The DFS rates at 6 months, 12 months, 18 months and 24 months after operation were compared between the two groups, the survival curve was drawn with the Kaplan-Meier Plotter, and a Cox regression model was established to analyze the factors affecting the recurrence and metastasis of TNBC after operation.,Results,2,①There was no significant difference in the DFS rate between the two groups at 6 months and 12 months after operation (,P,>,0.05). The DFS rates of the TCM-exposed group and the non-TCM-exposed group were 98.08% and 92.19% respectively at 18 months after operation, and the difference between the groups was statistically significant (,P,<,0.05). The DFS rates of the TCM-exposed group and the non-TCM-exposed group were 98.08% and 89.06% respectively at 24 months after operation, and the difference between the two groups was statistically significant (,P,<,0.05). ②The results of Cox regression analysis showed that the staging of metastatic lymph nodes (,P,<,0.001) and TCM intervention (,P,<,0.001) were factors affecting the recurrence and metastasis of TNBC patients after operation, among which TCM intervention was a protective factor [,HR,=0.191 (95% ,CI,: 0.083~0.443) ], the staging of metastatic lymph nodes was a risk factor, and the higher the grade is, the higher the risk of recurrence and metastasis will be. Age of onset, pathological grade, tumor size, percentage of Ki-67-positive cells, pathological type and with/without neoadjuvant chemotherapy were not related to prognosis (,P,>,0.05).,Conclusion,2,Sanyin Decoction has an adjuvant therapeutic effect on TNBC, which is beneficial to the improvement of DFS. The staging of metastatic lymph nodes is a risk factor for postoperative recurrence and metastasis of TNBC, while the intake of Sanyin Decoction is a protective factor.

关键词

三阴性乳腺癌三阴方生存分析队列研究

Keywords

triple-negative breast cancerSanyin Decoctionsurvival analysiscohort study

references

中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）乳腺癌诊疗指南[M]. 北京：人民卫生出版社，2019: 24.

杨文涛，步宏. 乳腺癌雌、孕激素受体免疫组织化学检测指南[J]. 中华病理学杂志，2015,44(4): 237-239.

《乳腺癌HER2检测指南（2019版）》编写组. 乳腺癌HER2检测指南（2019版）[J]. 中华病理学杂志，2019, 48(3): 169-175.

唐林，陈巍魏，管晓翔. AJCC第8版乳腺癌分期系统更新的解读[J]. 临床肿瘤学杂志，2017, 22(11): 1038-1040.

LIEDTKE C, MAZOUNI C, HESS K R, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275-1281.

JIANG Y Z, MA D, SUO C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers：Subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440.

董青，董雪燕，李忠，等. 基于中医古籍探索乳腺癌认知源流[J]. 北京中医药，2019, 38(4): 355-359.

DENT R, TRUDEAU M, PRITCHARD K I, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15 Pt 1): 4429-4434.

李嘉琪，栾瑾微，张玉，等. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志，2019, 33(3): 244-249.

胡钢，曾锦生，田秋红. 三阴性乳腺癌的临床特征分析[J]. 肿瘤综合治疗电子杂志，2019, 5(3): 40-43.

吴朔，姜翠，徐君南，等. 三阴性乳腺癌中Ki-67的表达及其临床病理意义[J]. 现代生物医学进展，2016, 16(28): 5455-5459.

马宁，杨艳芳，王世霞，等. 三阴性特殊类型乳腺癌患者的临床病理特征及预后[J]. 肿瘤，2019, 39(3): 196-203.

浏览量

550

下载量

CSCD

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于预后分析的复方绞股蓝胶囊预防口腔白斑癌变的回顾性队列研究

调脾疏肝益肾方联合化疗治疗三阴性乳腺癌术后复发患者的临床观察